TY - JOUR T1 - Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test JF - medRxiv DO - 10.1101/2021.05.07.21252267 SP - 2021.05.07.21252267 AU - Carmen W.E. Embregts AU - Babs Verstrepen AU - Jan A.M. Langermans AU - Kinga P. Böszörményi AU - Reina S. Sikkema AU - Rory D. de Vries AU - Donata Hoffmann AU - Kerstin Wernike AU - Lidwien A.M. Smit AU - Shan Zhao AU - Barry Rockx AU - Marion P.G. Koopmans AU - Bart L. Haagmans AU - Thijs Kuiken AU - Corine H. GeurtsvanKessel Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/07/2021.05.07.21252267.abstract N2 - Assays to measure SARS-CoV-2-specific neutralizing antibodies are important to monitor seroprevalence, to study asymptomatic infections and to reveal (intermediate) hosts. A recently developed assay, the surrogate virus-neutralization test (sVNT) is a quick and commercially available alternative to the “gold standard” virus neutralization assay using authentic virus, and does not require processing at BSL-3 level. The assay relies on the inhibition of binding of the receptor binding domain (RBD) on the spike (S) protein to human angiotensin-converting enzyme 2 (hACE2) by antibodies present in sera. As the sVNT does not require species- or isotype-specific conjugates, it can be similarly used for antibody detection in human and animal sera. In this study, we used 298 sera from PCR-confirmed COVID-19 patients and 151 sera from patients confirmed with other coronavirus or other (respiratory) infections, to evaluate the performance of the sVNT. To analyze the use of the assay in a One Health setting, we studied the presence of RBD-binding antibodies in 154 sera from nine animal species (cynomolgus and rhesus macaques, ferrets, rabbits, hamsters, cats, cattle, mink and dromedary camels). The sVNT showed a moderate to high sensitivity and a high specificity using sera from confirmed COVID-19 patients (91.3% and 100%, respectively) and animal sera (93.9% and 100%), however it lacked sensitivity to detect low titers. Significant correlations were found between the sVNT outcomes and PRNT50 and the Wantai total Ig and IgM ELISAs. While species-specific validation will be essential, our results show that the sVNT holds promise in detecting RBD-binding antibodies in multiple species.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The use of human specimens was approved by the Erasmus MC medical ethical committee (MEC approval: 2014 414), which allows the use of clinical data and left-over material from the specimen delivered to our laboratory for diagnostics, unless patients have declared they opted out of this scheme. Animal sera were obtained as left-over material from various infection experiments or field studies (mink and cats). Specific approval was obtained for each set of sera and can be found in the referred articles. Additional non-human primate sera were obtained from various experiments that were approved by the Dutch Central Committee for Animal Experiments (license: AVD5020020209404). Mink and cat sera were obtained by a certified veterinarian during a SARS-CoV-2 outbreak at a mink farm in the Netherlands. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made available upon request. ER -